Department of Cardiology, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania.
Department of Cardiology, Clinical Emergency Hospital of Bucharest, 014461 Bucharest, Romania.
Int J Mol Sci. 2021 Apr 30;22(9):4799. doi: 10.3390/ijms22094799.
Despite diagnostic and therapeutic advances, coronary artery disease and especially its extreme manifestation, ST elevation myocardial infarction (STEMI), remain the leading causes of morbidity and mortality worldwide. Early and prompt diagnosis is of great importance regarding the prognosis of STEMI patients. In recent years, microRNAs (miRNAs) have emerged as promising tools involved in many pathophysiological processes in various fields, including cardiovascular diseases. In acute coronary syndromes (ACS), circulating levels of miRNAs are significantly elevated, as an indicator of cardiac damage, making them a promising marker for early diagnosis of myocardial infarction. They also have prognostic value and great potential as therapeutic targets considering their key function in gene regulation. This review aims to summarize current information about miRNAs and their role as diagnostic, prognostic and therapeutic targets in STEMI patients.
尽管在诊断和治疗方面取得了进展,但冠状动脉疾病,尤其是其极端表现形式 ST 段抬高型心肌梗死(STEMI),仍然是全球发病率和死亡率的主要原因。早期和及时的诊断对于 STEMI 患者的预后非常重要。近年来,microRNAs(miRNAs)作为涉及包括心血管疾病在内的各个领域许多病理生理过程的有前途的工具而出现。在急性冠状动脉综合征(ACS)中,miRNAs 的循环水平显着升高,作为心脏损伤的指标,使它们成为心肌梗死早期诊断的有前途的标志物。鉴于它们在基因调控中的关键功能,它们还具有预后价值和作为治疗靶点的巨大潜力。这篇综述旨在总结有关 miRNAs 及其在 STEMI 患者中的诊断、预后和治疗靶点作用的最新信息。